Boehringer Ingelheim Initiates Long-term Study of Spesolimab for Hidradenitis Suppurativa
Boehringer Ingelheim is conducting a long-term study to evaluate the tolerance and efficacy of spesolimab in patients with hidradenitis suppurativa.
Asset / Drug
Drug and asset intelligence for spesolimab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.